Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13585219 | 0.79 | ACE2 (0.30) | — | |
| SCHEMBL22657546 | 0.79 | CES2 (0.34) | — | |
| SCHEMBL1428445 | 0.77 | EPHX2 (0.37) | RIPK1EPHX2 | |
| SCHEMBL18802737 | 0.76 | MEN1 (0.32) | — | |
| SCHEMBL1249623 | 0.75 | ERN1 (0.32) | — | |
| SCHEMBL2144865 | 0.74 | DGAT1 (0.31) | — | |
| SCHEMBL1428232 | 0.73 | ERN1 (0.40) | RIPK1 | |
| SCHEMBL2461361 | 0.73 | TAAR1 (0.55) | — | |
| SCHEMBL28699662 | 0.69 | LMNA (0.40) | EPHX2 | |
| SCHEMBL30434370 | 0.69 | DGAT1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2299816-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-2299816-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2013-11-13 | — | — | EP | disclosed |
| US-8420695-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420695-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420695-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8367706-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367706-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367706-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2010005841-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010005841-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009155156-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155156-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | RIPK1 148/4885EPHX2 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.